Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis

Lili Cheng; R. N. V. Krishna Deepak; Guoqiang Wang; Ziyi Meng; Lei Tao; Mengqing Xie; Wenna Chi; Yuming Zhang; Mingming Yang; Yilie Liao; Ruiqun Chen; Yu Liang; Junyu Zhang; Yuedong Huang; Weihua Wang; Zhiying Guo; Yunfang Wang; Jiandie D. Lin; Hao Fan; Ligong Chen

doi:10.1097/hep.0000000000000314

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Our findings reveal that SLC25A47, a hepatocyte-specific mitochondrial NAD + transporter, is one of the pharmacological targets of metformin and regulates lipid homeostasis through AMPKα, and may serve as a potential drug target for treating NAFLD and HCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cheng et al. (2023) studied this question.

synapsesocial.com/papers/69da7dad0d540cafc5839221 https://doi.org/10.1097/hep.0000000000000314

View Full Paper

Ask AI

Bookmark

Share

Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis

Ask about this paper

Abstract

Discussion

Cite This Study

Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading